KPV (Lys-Pro-Val)

Overview

KPV is a tripeptide consisting of the amino acids lysine-proline-valine (Lys-Pro-Val) with a molecular weight of approximately 342 Da. It is derived from the C-terminal sequence (positions 11-13) of alpha-melanocyte-stimulating hormone (alpha-MSH), a 13-amino acid neuropeptide with well-documented immunomodulatory properties. Remarkably, KPV retains the full anti-inflammatory potency of the parent alpha-MSH molecule despite comprising only three of its thirteen amino acids, while lacking alpha-MSH's melanogenic (skin-tanning) activity.

The discovery that the anti-inflammatory signaling of alpha-MSH resides in its terminal tripeptide fragment has generated significant research interest, particularly in inflammatory bowel disease (IBD) and mucosal immunology. KPV's small molecular size facilitates transport across biological membranes, including uptake via the intestinal peptide transporter PepT1, which is upregulated during intestinal inflammation.

Mechanism of Action

KPV exerts its anti-inflammatory effects through multiple converging signaling pathways:

• NF-kB inhibition: KPV directly inhibits the nuclear factor kappa-B (NF-kB) signaling cascade, a master regulator of inflammatory gene transcription. By blocking IkB kinase (IKK) activation and subsequent NF-kB nuclear translocation, KPV suppresses transcription of pro-inflammatory cytokines, chemokines, and adhesion molecules
• Melanocortin receptor signaling: KPV binds to melanocortin receptors MC1R and MC3R on immune cells, triggering intracellular cAMP elevation and protein kinase A activation, which further suppresses inflammatory signaling
• Cytokine modulation: KPV reduces secretion of pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-alpha), interleukin-1 beta (IL-1beta), and interleukin-6 (IL-6)
• MAP kinase inhibition: Suppression of mitogen-activated protein kinase (MAPK) inflammatory signaling pathways, reducing cellular stress responses
• PepT1-mediated uptake: In intestinal epithelial cells, KPV is actively transported via the peptide transporter PepT1, which is characteristically upregulated during inflammatory bowel disease, creating a targeted delivery mechanism to inflamed intestinal tissue

Research Evidence

The foundational work on alpha-MSH-derived anti-inflammatory peptides was advanced by Brzoska, Luger, and colleagues, who characterized the anti-inflammatory effects of melanocortin-derived peptides beyond the traditional pharmacophore (PMID: 21222263; PMID: 18612139). This research established that the C-terminal KPV tripeptide retains the immunomodulatory capacity of the full alpha-MSH molecule.

Kannengiesser et al. published a key study in Inflammatory Bowel Diseases demonstrating that KPV has anti-inflammatory potential in murine models of IBD. Orally administered KPV significantly decreased inflammation in both dextran sodium sulfate (DSS)-induced and 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis models, reducing colitis severity by over 50%.

Dalmasso et al. published in Gastroenterology (PMID: 18082178) establishing the PepT1-mediated transport mechanism. This study demonstrated that KPV is actively taken up by PepT1 in intestinal epithelial cells and immune cells, and that this transport mechanism mediates KPV's anti-inflammatory effects in models of colitis. The upregulation of PepT1 during intestinal inflammation creates a natural targeting mechanism.

Subsequent research (PMID: 27380407) identified a critical role for PepT1 in promoting colitis-associated cancer and demonstrated that KPV delivered via PepT1 provides therapeutic benefits in murine colitis-associated carcinogenesis models.

Potential Applications

• Inflammatory bowel disease: The most developed research area, with evidence of efficacy in multiple preclinical colitis models via oral administration
• Colitis-associated cancer prevention: PepT1-mediated KPV delivery has shown anti-tumorigenic effects in colitis-associated carcinogenesis models
• Dermatological inflammation: Topical applications for inflammatory skin conditions, leveraging the anti-inflammatory properties of the alpha-MSH pathway
• Mucosal immunity: Broad immunomodulatory effects on intestinal epithelial barrier function and mucosal immune cell populations
• Oral delivery potential: KPV's small size and PepT1-mediated uptake suggest feasibility for oral peptide delivery, which is unusual for bioactive peptides

Safety Considerations

As of 2026, KPV remains a research compound with no completed Phase I human safety trial and no FDA approval for any indication. The available safety data is derived entirely from preclinical animal studies.

In murine models, oral and systemic administration of KPV has been generally well tolerated, with no significant adverse effects reported at studied doses. The peptide's natural origin as a fragment of endogenous alpha-MSH provides some theoretical reassurance regarding biocompatibility, though this does not substitute for formal human safety evaluation.

KPV is subject to rapid proteolytic degradation in plasma, resulting in a short systemic half-life estimated at 1-2 hours, though tissue concentrations may persist longer due to PepT1-mediated accumulation in target tissues. The lack of melanogenic activity (unlike full-length alpha-MSH) eliminates concerns about pigmentation changes.

Potential risks that remain uncharacterized in humans include effects on immune surveillance with chronic immunosuppression, interactions with melanocortin receptor signaling in non-target tissues, and long-term consequences of NF-kB pathway modulation. Human clinical data are needed before any conclusions about safety can be drawn.